Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Oct;55(8):1826-1828.
doi: 10.1016/j.transproceed.2023.03.001. Epub 2023 Mar 21.

Elevated Tacrolimus Blood Concentration Due to the Interaction with Nirmatrelvir/Ritonavir During COVID-19 Treatment: A Case Report

Carlos Guzmán Cordero  1 , María Sáez-Torres de Vicente  2
Affiliations
Case Reports

Elevated Tacrolimus Blood Concentration Due to the Interaction with Nirmatrelvir/Ritonavir During COVID-19 Treatment: A Case Report

Carlos Guzmán Cordero et al. Transplant Proc. 2023 Oct.

Abstract

Nirmatrelvir/ritonavir, a newly authorized drug for the treatment of COVID-19, is a strong CYP3A4 inhibitor that can interact with many drugs, such as tacrolimus, reducing its metabolism. The reported case is a renal transplant patient who experienced a strong increase in tacrolimus blood concentration (up to 112ng/mL, more than ten times above the target range) when treated with both drugs at the same time, which caused a neurologic condition that required hospital admission for its control and treatment. The resolution of the symptoms was rapid, but the elevation of tacrolimus concentration remained for several days, even after discontinuing both drugs. This case shows the importance of developing a protocol for managing this interaction to guarantee the efficacy and safety of treatment with nirmatrelvir/ritonavir in transplant patients.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Evolution of tacrolimus blood concentration and its dosing regimen.
Fig 2
Fig 2
Evolution of serum creatinine.
See this image and copyright information in PMC

References

    1. Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. New Engl J Med. 2022;386:1397–1408. - PMC - PubMed
    1. Marzolini C, Kuritzkes DR, Marra F, Boyle A, Gibbons S, Flexner C, et al. Recommendations for the management of drug–drug interactions between the COVID -19 antiviral nirmatrelvir/ritonavir (Paxlovid) and comedications. Clin Pharmacol Ther. 2022;112:1191–1200. - PMC - PubMed
    1. Katzenmaier S, Markert C, Riedel KD, Burhenne J, Haefeli WE, Mikus G. Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using a limited sampling strategy. Clin Pharmacol Ther. 2011;90:666–673. - PubMed
    1. Pereira MR, Mohan S, Cohen DJ, Husain SA, Dube GK, Ratner LE, et al. COVID-19 in solid organ transplant recipients: initial report from the US epicenter. Am J Transplant. 2020;20:1800–1808. - PMC - PubMed
    1. Hiremath S, McGuinty M, Argyropoulos C, Brimble KS, Brown P, Chagla Z, et al. Prescribing nirmatrelvir/ritonavir (Paxlovid) for COVID-19 in advanced chronic kidney disease. Clin J Am Soc Nephrol. 2022;17:1247–1250. - PMC - PubMed

Publication types